We studied the relationship between serum erythropoietin (EPO) concentration and iron status in 67 patients undergoing chronic hemodialysis. Serum concentrations of EPO were measured by RIA with recombinant human EPO. The geometric mean of the serum EPO concentration was 10.9 mt. units/L (mean ± SD range = 7.8 -15.3 mt. units/L) in hemodialysis patients, considerably lower than that in normal subjects (12.9 mt. units/L). We found no significant correlation between concentrations of serum EPO and hemoglobin in hemodialysis patients, but found a significant negative correlation between serum concentrations of EPO and iron in hemodialysis patients. Moreover, we also found a significant positive correlation between the EPO concentration and the unsaturated iron-binding capacity (UIBC) in serum, and a significant negative correlation between the serum concentrations of EPO and ferritin in hemodialysis patients. Several patients who had relatively high EPO concentrations for hemodialysis patients also had low iron concentrations, high UIBC values, and low ferritin concentrations. These findings suggest that iron was utilized even at these EPO concentrations, which were very low for the degree of anemia observed in the hemodialysis patients. other forms of impaired oxygen delivery (5). The plasma EPO concentration has been measured by in vivo and in vitro bioaasays and by RIA involving highly purified urinary human EPO. The bioassays of EPO are relatively insensitive and nonspecific. However, widespread use of EPO RIAs has been limited by the availability of both highly purified urinary human EPO for the preparation of I-tracer and high-affinity anti-urinary human EPO antisera (6-10). The cloning and expression of the human EPO gene have provided large amounts of highly purified recombinant human EPO (rhEPO) for use in the development of sensitive and specific RIAs (11-13).
other forms of impaired oxygen delivery (5) .
The plasma EPO concentration has been measured by in vivo and in vitro bioaasays and by RIA involving highly purified urinary human EPO. The bioassays of EPO are relatively insensitive and nonspecific. However, widespread use of EPO RIAs has been limited by the availability of both highly purified urinary human EPO for the preparation of I-tracer and high-affinity anti-urinary human EPO antisera (6-10). The cloning and expression of the human EPO gene have provided large amounts of highly purified recombinant human EPO (rhEPO) for use in the development of sensitive and specific RIAs (11-13).
In the present study, we measured serum concentrations of EPO by RIA, with rhEPO in patients with chronic renal failure maintained by regular hemodialysis, and compared the results with the values obtained in normal subjects and patients with iron-deficiency anemia. We also measured iron, unsaturated iron-binding capacity (LJIBC), and ferritin concentrations in sera from hemodialysis patients and examined the relationships between these measurements and serum EPO concentrations.
Materials and Methods

Patientsand Controls
We studied normal, apparently healthy subjects and two groups of patients afier obtaining their informed consent ( Table 1) . The 80 normal subjects (35 women and 45 men), ages 27 to 65 (mean 45.7, SD 10.0) years, were controls for serum EPO concentrations.
All men had hemoglobin (Hb) concentrations >144) g/L and all women had Hb concentrations >120 g/L. None had intercurrent disease, e.g., proteinuria, renal disease, or liver disease.
The 20 patients (17 women and three men) we studied with various degrees of iron-deficiency anemia ranged in age from 29 to 69(50.0± 11.5) years. All had normal renal function, as determined by urinalysis and measurement of serum creatinine. Hb concentrations ranged from 40 to 113 (86 ± 21) g/L. Serum iron concentrations ranged from 200 to 510(319 ± 84) tg/L, and serum UIBC ranged from 3690 to 5610(4424 ± 510) g/L.
The 67 patients (29 women and 38 men) we studied with chronic renal failure, who bad been on intermittent hemodialysis for one to 189 (65.1 ± 55.4) months, ranged in age from 27 to 69 (51.7 ± 11.0) years. Bicarbonate dialysis was performed two or three times a Venous blood was drawn from normal subjects and patients with iron-deficiency anemia after an overnight fast, and immediately before hemodialysis in the hemodialysis patients. The serum was kept at -70 #{176}C until we measured serum EPO concentrations.
AlA of Serum EPO
We determined the serum concentrations of EPO with an RIA kit (Nippon DPC Corp., Tokyo, Japan) that included 'I-labeled rhEPO as the tracer, rabbit antiserum against rhEPO as the primary antibody, goat 
OtherTests
Hb serum creatinine concentrations were measured and reticulocytes counted by routine laboratory procedures. Concentrations of iron and UIBC in serum were measured by the bathophenanthroline method. Serum ferritin concentrations were measured by RIA (Baxter Corp., Tokyo, Japan).
Statistical Analysis
We performed the statistical evaluation by using Student's unpaired t-test, Pearson's correlation coefficient, and linear-regression analysis. Because serum EPO concentrations were log-normally distributed in the healthy subjects (Figure 1 ), we used geometric mean values and log-transformed data from serum EPO concentrations for the statistical evaluation. We also used log-transformed data for serum ferritin concentrations in hemodialysis patients. When mean values were arithmetic, the ranges were given as mean ± SD. P values <0.05 were considered significant.
Results
Normal subjects. The serum EPO concentrations ranged from 7.7 to 25.8 int. unitsfL, with a geometric (Figure 2 ). We found a negative correlation between serum concentrations of EPO and iron (r = -0.64, P <0.01), whereas serum EPO concentrations were not significantly correlated with serum UIBC.
Hemodialysis patients. Serum EPO concentrations in hemodialysis patients ranged from 6.4 to 28.4 hit. units/L, with a geometric mean of 10.9 (mean ± SD range = 7.8-15.3) mt. unitsfL. The mean serum EPO concentration was significantly less in these patients than in normal subjects (10.9 vs 12.9 mt. unitsfL, P <0.01); however, the hemodialysis patients had markedly lower Hb concentrations (77 ± 15 g/L). We found no significant relationship between serum EPO concentra- (Table 1) . We observed no significant relationship between serum EPO concentration and Hb concentration in hemodialysis patients (Figure 2) . However, serum EPO concentrations were significantly inversely correlated with serum concentrations of iron and ferritin (r = -0.25, P <0.05, and r = -0.24, P <0.05, respectively), and positively correlated with serum concentrations of UIBC in these patients (r = 0.32, P <0.01) (Figure 3) .
Serum EPO concentrations
were also significantly inversely correlated with serum creatinine concentrations (r = -0.33, P <0.01). However, when we divided the hemodialysis patients into two groups according to the frequency of hemodialysis, the mean serum EPO concentration was not greater in the patients who received hemodialysis twice a week (n = 34) than in those who received hemodialysis three times a week (n = 33). Concentrations of serum EPO were not correlated with the concentrations of serum creatiine in the patients who received hemodialysis three times a week.
Serum EPO concentrations demonstrated no correlation with reticulocyte counts or duration of hemodialysis. We found no significant difference in serum EPO concentrations between those patients whose renal failure was due to chronic glomerulonephritis and those with diabetic nephropathy (11.2 vs 11.1 uit. unita/L, respectively). 2, 1992 No significant difference was seen in the mean serum EPO concentrations between hemodialysia patients with a blood transfusion within one month (n = 8) and those without a blood transfusion within one month (n = 59), or between patients receiving androgen therapy (n = 16) and those not tioking androgen (n = 51). However, the mean serum EPO concentration was significantly greater in hemodialysis patients (n = 8) receiving iron treatment than in those not receiving it (n = 59): 15.1 vs 10.4 int. units/L (P <0.01) .
Hb concentrations were significantly inversely correlated with concentrations of iron and ferritin (r = -0.33, P <0.01, and r = -0.36, P <0.01, respectively) and were significantly positively correlated with UIBC concentrations (r = 0.53, P <0.001) (Figure 4) . We also found a significant correlation between Hb concentration and the duration of hemodialysis (r = 0.47, P <0.001) (Figure 5 ). Furthermore, in hemodialysis patients, serum iron concentrations were inversely correlated with UIBC concentrations (r = -0.68, P <0.001), and were positively correlated with serum ferritin concentrations (r = 0.54, P <0.001).
Discussion
A decrease in the concentration of Hb is well known to produce a marked increase in EPO concentration in patients with simple anemia not complicated by renal disease (9,14) . In the present study, the negative correlation between concentrations of Hb and serum EPO in patients with iron-deficiency anemia was observed as (14) , indicating that serum EPO concentrations in hemodialysis patients were markedly low for the degree of anemia.
In the present study, we also examined concentrations of serum iron, ULBC, and ferritin in hemodialysis patients. EPO stimulates erythropoiesis mainly by amplifying the pool of erythroid-committed cells in the bone marrow, and then initiates iron uptake and Hb synthesis (5) . Accordingly, the incorporation of 59Fe into erythrocytes or heme has been used to measure plasma EPO concentrations in bioassays (5,9).
Serum iron concentrations vary considerably in patients with chronic renal failure. Some investigators (15,16) have observed that serum concentrations of iron and UIBC were often decreased in patients with chronic renal failure. On the other hand, Finch et a!. (17) reported that dialysis patients with severe anemia requiring repeated transfusions had an increased plasma iron concentration, a prolonged iron turnover, a reduced had not only renal anemia attributable to decreased EPO production, but also irondeficiency anemia, because these patients had low serum iron and high UIBC concentrations.
Accordingly, these results suggest that iron was utilized even at these EPO concentrations, which were very low for the degree of anemia in these patients. This concept is also consistent with the findings that serum ferritin-the most useful variable for assessing iron stores (20)-was decreased in these patients.
In contrast, most hemodialysis patients who had relatively low EPO concentrations for hemodialysis patients had high serum iron concentrations, low serum UIBC concentrations, and high ferritin concentrations. These results suggest that iron was not utilized because of very low EPO concentrations in this group of patients, who had only pure renal anemia.
Therefore, correcting iron deficiency is valuable in hemodialysis patients with low serum concentrations of iron and ferritin, whose serum EPO concentrations are at least not lower than the normal range.
The significant correlation we demonstrated between Hb concentrations Ishikawa (22) reported that prolonging the dialysis period increased the incidence, number, and size of acquired renal cysts and that an improvement of hemathcrit in patients on long-term dialysis had also been noted, suggesting that the increased hematocrit was related to the acquired cystic disease of the kidney. Rhyner et al. (14) reported that a puncture of a solitary renal cyst decreased the serum EPO and hematocrit concentrations, and the accumulation of cystic fluid in a renal cyst increased the serum EPO and hematocrit concentrations in a patient who had secondary polycythemia due to a solitary renal cyst. However, we found no relationship between serum EPO concentration and the duration of hemodialysis in hemodialysis patients, even though Ohigashi et al. (12) did find a significant correlation.
